123 related articles for article (PubMed ID: 37423893)
1. Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.
Patnana PK; Liu L; Frank D; Nimmagadda SC; Behrens M; Ahmed H; Xie X; Liebmann M; Wei L; Gerdemann A; Thivakaran A; Humpf HU; Klotz L; Dugas M; Varghese J; Trajkovic-Arsic M; Siveke JT; Hanenberg H; Opalka B; Dührsen U; Reinhardt HC; Guenther U; von Bubnoff N; Khandanpour C
Br J Haematol; 2023 Sep; 202(5):1033-1048. PubMed ID: 37423893
[TBL] [Abstract][Full Text] [Related]
2. GFI1 as a novel prognostic and therapeutic factor for AML/MDS.
Hönes JM; Botezatu L; Helness A; Vadnais C; Vassen L; Robert F; Hergenhan SM; Thivakaran A; Schütte J; Al-Matary YS; Lams RF; Fraszscak J; Makishima H; Radivoyevitch T; Przychodzen B; da Conceição Castro SV; Görgens A; Giebel B; Klein-Hitpass L; Lennartz K; Heuser M; Thiede C; Ehninger G; Dührsen U; Maciejewski JP; Möröy T; Khandanpour C
Leukemia; 2016 Jun; 30(6):1237-45. PubMed ID: 26847026
[TBL] [Abstract][Full Text] [Related]
3. Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS).
Xie X; Frank D; Patnana PK; Schütte J; Al-Matary Y; Liu L; Wei L; Dugas M; Varghese J; Nimmagadda SC; Khandanpour C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008835
[TBL] [Abstract][Full Text] [Related]
4. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
[TBL] [Abstract][Full Text] [Related]
5. Enforced GFI1 expression impedes human and murine leukemic cell growth.
Hönes JM; Thivakaran A; Botezatu L; Patnana P; Castro SVDC; Al-Matary YS; Schütte J; Fischer KBI; Vassen L; Görgens A; Dührsen U; Giebel B; Khandanpour C
Sci Rep; 2017 Nov; 7(1):15720. PubMed ID: 29147018
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of growth factor independence 1 expression in patients with
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Allahbakhshian A; Farsani MA
J Cancer Res Ther; 2020; 16(1):23-27. PubMed ID: 32362605
[TBL] [Abstract][Full Text] [Related]
7. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
8. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
Khandanpour C; Thiede C; Valk PJ; Sharif-Askari E; Nückel H; Lohmann D; Horsthemke B; Siffert W; Neubauer A; Grzeschik KH; Bloomfield CD; Marcucci G; Maharry K; Slovak ML; van der Reijden BA; Jansen JH; Schackert HK; Afshar K; Schnittger S; Peeters JK; Kroschinsky F; Ehninger G; Lowenberg B; Dührsen U; Möröy T
Blood; 2010 Mar; 115(12):2462-72. PubMed ID: 20075157
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Dawson MA; Prinjha RK; Dittmann A; Giotopoulos G; Bantscheff M; Chan WI; Robson SC; Chung CW; Hopf C; Savitski MM; Huthmacher C; Gudgin E; Lugo D; Beinke S; Chapman TD; Roberts EJ; Soden PE; Auger KR; Mirguet O; Doehner K; Delwel R; Burnett AK; Jeffrey P; Drewes G; Lee K; Huntly BJ; Kouzarides T
Nature; 2011 Oct; 478(7370):529-33. PubMed ID: 21964340
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of high GFI1 expression in AML of normal karyotype and its association with a FLT3-ITD signature.
Volpe G; Walton DS; Grainger DE; Ward C; Cauchy P; Blakemore D; Coleman DJL; Cockerill PN; Garcia P; Frampton J
Sci Rep; 2017 Sep; 7(1):11148. PubMed ID: 28894287
[TBL] [Abstract][Full Text] [Related]
11. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
Botezatu L; Michel LC; Helness A; Vadnais C; Makishima H; Hönes JM; Robert F; Vassen L; Thivakaran A; Al-Matary Y; Lams RF; Schütte J; Giebel B; Görgens A; Heuser M; Medyouf H; Maciejewski J; Dührsen U; Möröy T; Khandanpour C
Exp Hematol; 2016 Aug; 44(8):713-726.e14. PubMed ID: 27216773
[TBL] [Abstract][Full Text] [Related]
13. Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation.
Heuts BMH; Arza-Apalategi S; Alkema SG; Tijchon E; Jussen L; Bergevoet SM; van der Reijden BA; Martens JHA
Cells; 2023 Apr; 12(8):. PubMed ID: 37190104
[TBL] [Abstract][Full Text] [Related]
14. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
[TBL] [Abstract][Full Text] [Related]
15. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
[TBL] [Abstract][Full Text] [Related]
16. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
[TBL] [Abstract][Full Text] [Related]
17. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
[TBL] [Abstract][Full Text] [Related]
18. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
[TBL] [Abstract][Full Text] [Related]
19. Relationships between AML1-ETO and MLL-AF9 fusion gene expressions and hematological parameters in acute myeloid leukemia.
Muddathir ARM; Hamid TAM; Mohamed Elamin E; Khabour OF
Gulf J Oncolog; 2020 Sep; 1(34):65-69. PubMed ID: 33431365
[TBL] [Abstract][Full Text] [Related]
20. The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia.
Wang H; Bei L; Shah CA; Huang W; Platanias LC; Eklund EA
Oncogene; 2018 May; 37(19):2532-2544. PubMed ID: 29459712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
